The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours Abstract #1107

Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.
Aim(s): We present CAM as a suitable model for in vivo studying of gastrointestinal neuroendocrine tumours (GI-NET).
Materials and methods: Two small intestine GI-NET cell lines (P-STS and KRJ-I) and 4 patient derived GI-NET tumour tissues were grafted on CAM for 72-120 hours at 37°C. Xenografts were observed by light microscopy and tissues were stained for NET specific markers as chromogranin A and synaptophysin. Mitogenic activity was assessed by Ki-67.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: PhD Nassim Ghaffari Tabrizi-Wizsy

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1528 Medullary Thyroid Carcinoma Cell Lines – An Update
Introduction: Medullary Thyroid Carcinoma (MTC) originates from calcitonin-producing neuroendocrine C-cells of the thyroid gland. Mutations in the RET-proto-oncogene are associated with both sporadic and familial MTC. As MTC are poorly responsive to chemo- and radiation- therapy, surgery is the only curative treatment at the moment. The cytogenetics of MTC have been sparsely investigated because the cells are very difficult to cultivate. In the last three decades our research group has established 10 continues cell lines derived from primary tumor and lymph node metastasis of patients with either sporadic or hereditary MTC.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Gert Schwach
#2684 Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection
Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) are steadily increasing in prevalence and present several clinical challenges.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Wuhu Zhang
Authors: Zhang W, Wang W, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, ...